Aarey Drugs & Pharmaceuticals Limited
NSE: AAREYDRUGS · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Aarey Drugs & Pharmaceuticals Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Aarey Drugs & Pharmaceuticals Ltd is an Indian manufacturer specialising in Active Pharmaceutical Ingredients (APIs), bulk drugs, and intermediates. The company also engages in the trading of industrial solvents and specialty chemicals for diverse industrial applications.
Business Model
The company generates revenue through the manufacturing and sale of pharmaceutical ingredients and the trading of chemical commodities. It serves a client base primarily consisting of pharmaceutical formulation manufacturers and merchant exporters.
Growth Outlook
Growth is driven by the sustained demand for APIs and chemical intermediates within the domestic and international pharmaceutical formulation sectors. The company continues to leverage its manufacturing capabilities to support merchant exports.
Key Risks
- Regulatory Compliance. The company faces risks related to stringent quality standards and regulatory inspections by health authorities in the pharmaceutical sector.
- Raw Material Price Volatility. Fluctuations in the cost of chemical inputs and solvents can significantly impact profit margins due to the commodity nature of trading.
- Market Competition. The API and bulk drug manufacturing industry is highly fragmented, leading to intense price competition from both domestic and international players.
- Foreign Exchange Risk. As a participant in merchant exports, the company is exposed to currency fluctuations that may affect the profitability of international transactions.
Start your research today
Unlock AI insights, financials, peers and live data on Aarey Drugs & Pharmaceuticals Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹472 Cr
TTM · standalone
NET PROFIT
₹5 Cr
TTM · standalone
EPS
₹1.59
TTM · standalone
RETURN ON EQUITY
3.7%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
7.2%
TTM · standalone
P/E
65.3x
Q4 FY26 · standalone
EV/EBITDA
25.6x
Q4 FY26 · standalone
EBITDA MARGIN
2.8%
TTM · standalone
NET PROFIT MARGIN
0.8%
Q4 FY26 · standalone
DEBT TO EQUITY
0.3x
Q4 FY26 · standalone
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Aarey Drugs & Pharmaceuticals LimitedAAREYDRUGS | ₹291 Cr | 65.31 | 25.59 | -0.4% | 2.8% | 3.7% | 7.2% | +23.8% |
TranschemTRANSCHEM | ₹502 Cr | 75.62 | 52.99 | -100.0% | 177.7% | 8.3% | 10.6% | +600.8% |
Albert DavidALBERTDAVD | ₹501 Cr | 21.67 | 13.19 | 11.4% | 11.0% | 5.8% | 7.5% | +10.3% |
Haleos Labs LimitedHALEOSLABS | ₹457 Cr | 28.51 | 12.83 | -3.1% | 13.6% | 7.4% | 10.3% | — |
Medicamen BiotecMEDICAMEQ | ₹434 Cr | 43.00 | 19.76 | 24.7% | 11.3% | 4.1% | 6.2% | +5.9% |
Jenburkt Pharmaceuticals LimitedJENBURPH | ₹420 Cr | 12.30 | 8.20 | — | 30.0% | 16.7% | 21.5% | -15.2% |
As of Q4 FY26
Financials
Aarey Drugs & Pharmaceuticals Limited
NSE: AAREYDRUGS · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Aarey Drugs & Pharmaceuticals Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Aarey Drugs & Pharmaceuticals Ltd is an Indian manufacturer specialising in Active Pharmaceutical Ingredients (APIs), bulk drugs, and intermediates. The company also engages in the trading of industrial solvents and specialty chemicals for diverse industrial applications.
Business Model
The company generates revenue through the manufacturing and sale of pharmaceutical ingredients and the trading of chemical commodities. It serves a client base primarily consisting of pharmaceutical formulation manufacturers and merchant exporters.
Growth Outlook
Growth is driven by the sustained demand for APIs and chemical intermediates within the domestic and international pharmaceutical formulation sectors. The company continues to leverage its manufacturing capabilities to support merchant exports.
Key Risks
- Regulatory Compliance. The company faces risks related to stringent quality standards and regulatory inspections by health authorities in the pharmaceutical sector.
- Raw Material Price Volatility. Fluctuations in the cost of chemical inputs and solvents can significantly impact profit margins due to the commodity nature of trading.
- Market Competition. The API and bulk drug manufacturing industry is highly fragmented, leading to intense price competition from both domestic and international players.
- Foreign Exchange Risk. As a participant in merchant exports, the company is exposed to currency fluctuations that may affect the profitability of international transactions.
Start your research today
Unlock AI insights, financials, peers and live data on Aarey Drugs & Pharmaceuticals Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹472 Cr
TTM · standalone
NET PROFIT
₹5 Cr
TTM · standalone
EPS
₹1.59
TTM · standalone
RETURN ON EQUITY
3.7%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
7.2%
TTM · standalone
P/E
65.3x
Q4 FY26 · standalone
EV/EBITDA
25.6x
Q4 FY26 · standalone
EBITDA MARGIN
2.8%
TTM · standalone
NET PROFIT MARGIN
0.8%
Q4 FY26 · standalone
DEBT TO EQUITY
0.3x
Q4 FY26 · standalone
Peers · Pharmaceuticals
As of Q4 FY26